Eikon Therapeutics: Funding, Investors & Team (Oct 2026)
Eikon Therapeutics is a biopharmaceutical company that specializes in creating new technologies for drug discovery. They use advanced microscopy and engineering techniques to develop innovative therapeutic options, aiming to improve understanding of cellular processes and support the development of targeted treatments. By integrating biology, engineering, and chemistry, Eikon Therapeutics aims to streamline the drug discovery process and expand their pipeline of potential medications through proprietary platforms.
Eikon Therapeutics has raised $975M across 3 funding rounds on record, the most recent a Series D of $351M announced in Feb 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Eikon Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Eikon Therapeutics Funding Rounds
Eikon Therapeutics raised $518M in a Series B announced in Jan 2022.
1.4 years later, a Series C of $106M was announced in Jun 2023.
1.7 years later, a Series D of $351M was announced in Feb 2025.
Eikon Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Eikon Therapeutics Funding Compared to Other Biotechnology Startups
Eikon Therapeutics' latest round of $351M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Eikon Therapeutics in Biotechnology and Hayward
Companies Similar to Eikon Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Eikon Therapeutics Funding FAQs
What does Eikon Therapeutics do?
Eikon Therapeutics is a biopharmaceutical company that specializes in creating new technologies for drug discovery. They use advanced microscopy and engineering techniques to develop innovative therapeutic options, aiming to improve understanding of cellular processes and support the development of targeted treatments. By integrating biology, engineering, and chemistry, Eikon Therapeutics aims to streamline the drug discovery process and expand their pipeline of potential medications through proprietary platforms.
How much funding has Eikon Therapeutics raised?
Eikon Therapeutics has raised $975M across 3 rounds on record. The most recent is a Series D of $351M announced in Feb 2025.
When did Eikon Therapeutics last raise funding?
Eikon Therapeutics' most recent funding round on record is a Series D of $351M, announced in Feb 2025.
Who founded Eikon Therapeutics?
FundedIQ lists Luke Lavi (Founder), Xavier Darzacq (Founder) at Eikon Therapeutics.
Who is the CEO of Eikon Therapeutics?
Roger Perlmutter is listed as CEO at Eikon Therapeutics.
Where is Eikon Therapeutics headquartered?
Eikon Therapeutics is based in Hayward, California, United States.
How many employees does Eikon Therapeutics have?
Eikon Therapeutics is in the 251-500 employee band.
How does Eikon Therapeutics' funding compare to other Biotechnology startups?
Eikon Therapeutics' latest round of $351M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Eikon Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Eikon Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.